We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors.
- Authors
Yu Jin Cha; Mi-Sook Kim; Won-Il Jang; Young Seok Seo; Chul Koo Cho; Hyung Jun Yoo; Eun Kyung Paik
- Abstract
Purpose: To evaluate the outcomes of stereotactic body radiation therapy (SBRT) for patients with liver oligo-recurrence and oligo-progression from various primary tumors. Materials and Methods: Between 2002 and 2013, 72 patients with liver oligo-recurrence (oligo-metastasis with a controlled primary tumor) and oligo-progression (contradictory progression of a few sites of disease despite an overall tumor burden response to therapy) underwent SBRT. Of these, 9 and 8 patients with uncontrollable distant metastases and patients immediate loss to follow-up, respectively, were excluded. The total planning target volume was used to select the SBRT dose (median, 48 Gy; range, 30 to 60 Gy, 3-4 fractions). Toxicity was evaluated using the Common Toxicity Criteria for Adverse Events v4.0. Results: We evaluated 55 patients (77 lesions) treated with SBRT for liver metastases. All patients had controlled primary lesions, and 28 patients had stable lesions at another site (oligo-progression). The most common primary site was the colon (36 patients), followed by the stomach (6 patients) and other sites (13 patients). The 2-year local control and progression-free survival rates were 68% and 22%, respectively. The 2- and 5-year overall survival rates were 56% and 20%, respectively. The most common adverse events were grade 1-2 fatigue, nausea, and vomiting; no grade ≥3 toxicities were observed. Univariate analysis revealed that oligoprogression associated with poor survival. Conclusion: SBRT for liver oligo-recurrence and oligo-progression appears safe, with similar local control rates. For liver oligoprogression, criteria are needed to select patients in whom improved overall survival can be expected through SBRT.
- Subjects
STEREOTACTIC radiotherapy; LIVER diseases; DISEASE relapse; DISEASE progression; TUMOR treatment
- Publication
Radiation Oncology Journal, 2017, Vol 35, Issue 2, p172
- ISSN
2234-1900
- Publication type
Article
- DOI
10.3857/roj.2017.00024